COVID-19 Impact on Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, Status and Forecast 2020-2026

COVID-19 Impact on Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, Status and Forecast 2020-2026

Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Squamous Non-Small Cell Lung Cancer Therapeutics Revenue
1.4 Market Analysis by Type
1.4.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 BMS-906024
1.4.3 Buparlisib Hydrochloride
1.4.4 FP-1039
1.4.5 Ipilimumab
1.4.6 JNJ-42756493
1.4.7 Lenvatinib
1.4.8 Others
1.5 Market by Application
1.5.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Application: 2020 VS 2026
1.5.2 Research Center
1.5.3 Hospital
1.5.4 Clinic
1.6 Coronavirus Disease 2019 (Covid-19): Squamous Non-Small Cell Lung Cancer Therapeutics Industry Impact
1.6.1 How the Covid-19 is Affecting the Squamous Non-Small Cell Lung Cancer Therapeutics Industry
1.6.1.1 Squamous Non-Small Cell Lung Cancer Therapeutics Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19's Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Squamous Non-Small Cell Lung Cancer Therapeutics Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Squamous Non-Small Cell Lung Cancer Therapeutics Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 Global Growth Trends by Regions
2.1 Squamous Non-Small Cell Lung Cancer Therapeutics Market Perspective (2015-2026)
2.2 Squamous Non-Small Cell Lung Cancer Therapeutics Growth Trends by Regions
2.2.1 Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Squamous Non-Small Cell Lung Cancer Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 Squamous Non-Small Cell Lung Cancer Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter's Five Forces Analysis
2.3.5 Squamous Non-Small Cell Lung Cancer Therapeutics Market Growth Strategy
2.3.6 Primary Interviews with Key Squamous Non-Small Cell Lung Cancer Therapeutics Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Squamous Non-Small Cell Lung Cancer Therapeutics Players by Market Size
3.1.1 Global Top Squamous Non-Small Cell Lung Cancer Therapeutics Players by Revenue (2015-2020)
3.1.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Players (2015-2020)
3.1.3 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Concentration Ratio
3.2.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in 2019
3.3 Squamous Non-Small Cell Lung Cancer Therapeutics Key Players Head office and Area Served
3.4 Key Players Squamous Non-Small Cell Lung Cancer Therapeutics Product Solution and Service
3.5 Date of Enter into Squamous Non-Small Cell Lung Cancer Therapeutics Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type (2015-2026)
4.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Forecasted Market Size by Type (2021-2026)
5 Squamous Non-Small Cell Lung Cancer Therapeutics Breakdown Data by Application (2015-2026)
5.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020)
5.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (2015-2020)
6.2 Squamous Non-Small Cell Lung Cancer Therapeutics Key Players in North America (2019-2020)
6.3 North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Type (2015-2020)
6.4 North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020)
7 Europe
7.1 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (2015-2020)
7.2 Squamous Non-Small Cell Lung Cancer Therapeutics Key Players in Europe (2019-2020)
7.3 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Type (2015-2020)
7.4 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020)
8 China
8.1 China Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (2015-2020)
8.2 Squamous Non-Small Cell Lung Cancer Therapeutics Key Players in China (2019-2020)
8.3 China Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Type (2015-2020)
8.4 China Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020)
9 Japan
9.1 Japan Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (2015-2020)
9.2 Squamous Non-Small Cell Lung Cancer Therapeutics Key Players in Japan (2019-2020)
9.3 Japan Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Type (2015-2020)
9.4 Japan Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (2015-2020)
10.2 Squamous Non-Small Cell Lung Cancer Therapeutics Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Type (2015-2020)
10.4 Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020)
11 India
11.1 India Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (2015-2020)
11.2 Squamous Non-Small Cell Lung Cancer Therapeutics Key Players in India (2019-2020)
11.3 India Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Type (2015-2020)
11.4 India Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (2015-2020)
12.2 Squamous Non-Small Cell Lung Cancer Therapeutics Key Players in Central & South America (2019-2020)
12.3 Central & South America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Type (2015-2020)
12.4 Central & South America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Ascenta Therapeutics, Inc.
13.1.1 Ascenta Therapeutics, Inc. Company Details
13.1.2 Ascenta Therapeutics, Inc. Business Overview and Its Total Revenue
13.1.3 Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
13.1.4 Ascenta Therapeutics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020))
13.1.5 Ascenta Therapeutics, Inc. Recent Development
13.2 AstraZeneca Plc
13.2.1 AstraZeneca Plc Company Details
13.2.2 AstraZeneca Plc Business Overview and Its Total Revenue
13.2.3 AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
13.2.4 AstraZeneca Plc Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020)
13.2.5 AstraZeneca Plc Recent Development
13.3 AVEO Pharmaceuticals, Inc.
13.3.1 AVEO Pharmaceuticals, Inc. Company Details
13.3.2 AVEO Pharmaceuticals, Inc. Business Overview and Its Total Revenue
13.3.3 AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
13.3.4 AVEO Pharmaceuticals, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020)
13.3.5 AVEO Pharmaceuticals, Inc. Recent Development
13.4 Bayer AG
13.4.1 Bayer AG Company Details
13.4.2 Bayer AG Business Overview and Its Total Revenue
13.4.3 Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
13.4.4 Bayer AG Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020)
13.4.5 Bayer AG Recent Development
13.5 BIND Therapeutics, Inc.
13.5.1 BIND Therapeutics, Inc. Company Details
13.5.2 BIND Therapeutics, Inc. Business Overview and Its Total Revenue
13.5.3 BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
13.5.4 BIND Therapeutics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020)
13.5.5 BIND Therapeutics, Inc. Recent Development
13.6 Boehringer Ingelheim GmbH
13.6.1 Boehringer Ingelheim GmbH Company Details
13.6.2 Boehringer Ingelheim GmbH Business Overview and Its Total Revenue
13.6.3 Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
13.6.4 Boehringer Ingelheim GmbH Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020)
13.6.5 Boehringer Ingelheim GmbH Recent Development
13.7 Bristol-Myers Squibb Company
13.7.1 Bristol-Myers Squibb Company Company Details
13.7.2 Bristol-Myers Squibb Company Business Overview and Its Total Revenue
13.7.3 Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
13.7.4 Bristol-Myers Squibb Company Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020)
13.7.5 Bristol-Myers Squibb Company Recent Development
13.8 Eli Lilly and Company
13.8.1 Eli Lilly and Company Company Details
13.8.2 Eli Lilly and Company Business Overview and Its Total Revenue
13.8.3 Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
13.8.4 Eli Lilly and Company Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020)
13.8.5 Eli Lilly and Company Recent Development
13.9 F. Hoffmann-La Roche Ltd.
13.9.1 F. Hoffmann-La Roche Ltd. Company Details
13.9.2 F. Hoffmann-La Roche Ltd. Business Overview and Its Total Revenue
13.9.3 F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
13.9.4 F. Hoffmann-La Roche Ltd. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020)
13.9.5 F. Hoffmann-La Roche Ltd. Recent Development
13.10 Five Prime Therapeutics, Inc.
13.10.1 Five Prime Therapeutics, Inc. Company Details
13.10.2 Five Prime Therapeutics, Inc. Business Overview and Its Total Revenue
13.10.3 Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
13.10.4 Five Prime Therapeutics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020)
13.10.5 Five Prime Therapeutics, Inc. Recent Development
13.11 Genentech, Inc.
10.11.1 Genentech, Inc. Company Details
10.11.2 Genentech, Inc. Business Overview and Its Total Revenue
10.11.3 Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
10.11.4 Genentech, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020)
10.11.5 Genentech, Inc. Recent Development
13.12 Incyte Corporation
10.12.1 Incyte Corporation Company Details
10.12.2 Incyte Corporation Business Overview and Its Total Revenue
10.12.3 Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
10.12.4 Incyte Corporation Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020)
10.12.5 Incyte Corporation Recent Development
13.13 Johnson & Johnson
10.13.1 Johnson & Johnson Company Details
10.13.2 Johnson & Johnson Business Overview and Its Total Revenue
10.13.3 Johnson & Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
10.13.4 Johnson & Johnson Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020)
10.13.5 Johnson & Johnson Recent Development
13.14 MacroGenics, Inc.
10.14.1 MacroGenics, Inc. Company Details
10.14.2 MacroGenics, Inc. Business Overview and Its Total Revenue
10.14.3 MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
10.14.4 MacroGenics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020)
10.14.5 MacroGenics, Inc. Recent Development
13.15 Novartis AG
10.15.1 Novartis AG Company Details
10.15.2 Novartis AG Business Overview and Its Total Revenue
10.15.3 Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
10.15.4 Novartis AG Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020)
10.15.5 Novartis AG Recent Development
13.16 Oncogenex Pharmaceuticals, Inc.
10.16.1 Oncogenex Pharmaceuticals, Inc. Company Details
10.16.2 Oncogenex Pharmaceuticals, Inc. Business Overview and Its Total Revenue
10.16.3 Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
10.16.4 Oncogenex Pharmaceuticals, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020)
10.16.5 Oncogenex Pharmaceuticals, Inc. Recent Development
13.17 PsiOxus Therapeutics Limited
10.17.1 PsiOxus Therapeutics Limited Company Details
10.17.2 PsiOxus Therapeutics Limited Business Overview and Its Total Revenue
10.17.3 PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
10.17.4 PsiOxus Therapeutics Limited Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020)
10.17.5 PsiOxus Therapeutics Limited Recent Development
14 Analyst's Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
List of Tables
Table 1. Squamous Non-Small Cell Lung Cancer Therapeutics Key Market Segments
Table 2. Key Players Covered: Ranking by Squamous Non-Small Cell Lung Cancer Therapeutics Revenue
Table 3. Ranking of Global Top Squamous Non-Small Cell Lung Cancer Therapeutics Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of BMS-906024
Table 6. Key Players of Buparlisib Hydrochloride
Table 7. Key Players of FP-1039
Table 8. Key Players of Ipilimumab
Table 9. Key Players of JNJ-42756493
Table 10. Key Players of Lenvatinib
Table 11. Key Players of Others
Table 12. COVID-19 Impact Global Market: (Four Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Forecast Scenarios)
Table 13. Opportunities and Trends for Squamous Non-Small Cell Lung Cancer Therapeutics Players in the COVID-19 Landscape
Table 14. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 15. Key Regions/Countries Measures against Covid-19 Impact
Table 16. Proposal for Squamous Non-Small Cell Lung Cancer Therapeutics Players to Combat Covid-19 Impact
Table 17. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 18. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Regions (US$ Million): 2020 VS 2026
Table 19. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Regions (2015-2020) (US$ Million)
Table 20. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Regions (2015-2020)
Table 21. Global Squamous Non-Small Cell Lung Cancer Therapeutics Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 22. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Regions (2021-2026)
Table 23. Market Top Trends
Table 24. Key Drivers: Impact Analysis
Table 25. Key Challenges
Table 26. Squamous Non-Small Cell Lung Cancer Therapeutics Market Growth Strategy
Table 27. Main Points Interviewed from Key Squamous Non-Small Cell Lung Cancer Therapeutics Players
Table 28. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Players (2015-2020) (Million US$)
Table 29. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Players (2015-2020)
Table 30. Global Top Squamous Non-Small Cell Lung Cancer Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics as of 2019)
Table 31. Global Squamous Non-Small Cell Lung Cancer Therapeutics by Players Market Concentration Ratio (CR5 and HHI)
Table 32. Key Players Headquarters and Area Served
Table 33. Key Players Squamous Non-Small Cell Lung Cancer Therapeutics Product Solution and Service
Table 34. Date of Enter into Squamous Non-Small Cell Lung Cancer Therapeutics Market
Table 35. Mergers & Acquisitions, Expansion Plans
Table 36. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 37. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Share by Type (2015-2020)
Table 38. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Type (2021-2026)
Table 39. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Share by Application (2015-2020)
Table 40. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 41. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Share by Application (2021-2026)
Table 42. North America Key Players Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (2019-2020) (Million US$)
Table 43. North America Key Players Squamous Non-Small Cell Lung Cancer Therapeutics Market Share (2019-2020)
Table 44. North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 45. North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Type (2015-2020)
Table 46. North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 47. North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Application (2015-2020)
Table 48. Europe Key Players Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (2019-2020) (Million US$)
Table 49. Europe Key Players Squamous Non-Small Cell Lung Cancer Therapeutics Market Share (2019-2020)
Table 50. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 51. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Type (2015-2020)
Table 52. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 53. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Application (2015-2020)
Table 54. China Key Players Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (2019-2020) (Million US$)
Table 55. China Key Players Squamous Non-Small Cell Lung Cancer Therapeutics Market Share (2019-2020)
Table 56. China Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 57. China Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Type (2015-2020)
Table 58. China Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 59. China Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Application (2015-2020)
Table 60. Japan Key Players Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (2019-2020) (Million US$)
Table 61. Japan Key Players Squamous Non-Small Cell Lung Cancer Therapeutics Market Share (2019-2020)
Table 62. Japan Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 63. Japan Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Type (2015-2020)
Table 64. Japan Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 65. Japan Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Application (2015-2020)
Table 66. Southeast Asia Key Players Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (2019-2020) (Million US$)
Table 67. Southeast Asia Key Players Squamous Non-Small Cell Lung Cancer Therapeutics Market Share (2019-2020)
Table 68. Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 69. Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Type (2015-2020)
Table 70. Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 71. Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Application (2015-2020)
Table 72. India Key Players Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (2019-2020) (Million US$)
Table 73. India Key Players Squamous Non-Small Cell Lung Cancer Therapeutics Market Share (2019-2020)
Table 74. India Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 75. India Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Type (2015-2020)
Table 76. India Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 77. India Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Application (2015-2020)
Table 78. Central & South America Key Players Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (2019-2020) (Million US$)
Table 79. Central & South America Key Players Squamous Non-Small Cell Lung Cancer Therapeutics Market Share (2019-2020)
Table 80. Central & South America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 81. Central & South America Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Type (2015-2020)
Table 82. Central & South America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 83. Central & South America Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Application (2015-2020)
Table 84. Ascenta Therapeutics, Inc. Company Details
Table 85. Ascenta Therapeutics, Inc. Business Overview
Table 86. Ascenta Therapeutics, Inc. Product
Table 87. Ascenta Therapeutics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020) (Million US$)
Table 88. Ascenta Therapeutics, Inc. Recent Development
Table 89. AstraZeneca Plc Company Details
Table 90. AstraZeneca Plc Business Overview
Table 91. AstraZeneca Plc Product
Table 92. AstraZeneca Plc Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020) (Million US$)
Table 93. AstraZeneca Plc Recent Development
Table 94. AVEO Pharmaceuticals, Inc. Company Details
Table 95. AVEO Pharmaceuticals, Inc. Business Overview
Table 96. AVEO Pharmaceuticals, Inc. Product
Table 97. AVEO Pharmaceuticals, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020) (Million US$)
Table 98. AVEO Pharmaceuticals, Inc. Recent Development
Table 99. Bayer AG Company Details
Table 100. Bayer AG Business Overview
Table 101. Bayer AG Product
Table 102. Bayer AG Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020) (Million US$)
Table 103. Bayer AG Recent Development
Table 104. BIND Therapeutics, Inc. Company Details
Table 105. BIND Therapeutics, Inc. Business Overview
Table 106. BIND Therapeutics, Inc. Product
Table 107. BIND Therapeutics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020) (Million US$)
Table 108. BIND Therapeutics, Inc. Recent Development
Table 109. Boehringer Ingelheim GmbH Company Details
Table 110. Boehringer Ingelheim GmbH Business Overview
Table 111. Boehringer Ingelheim GmbH Product
Table 112. Boehringer Ingelheim GmbH Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020) (Million US$)
Table 113. Boehringer Ingelheim GmbH Recent Development
Table 114. Bristol-Myers Squibb Company Company Details
Table 115. Bristol-Myers Squibb Company Business Overview
Table 116. Bristol-Myers Squibb Company Product
Table 117. Bristol-Myers Squibb Company Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020) (Million US$)
Table 118. Bristol-Myers Squibb Company Recent Development
Table 119. Eli Lilly and Company Business Overview
Table 120. Eli Lilly and Company Product
Table 121. Eli Lilly and Company Company Details
Table 122. Eli Lilly and Company Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020) (Million US$)
Table 123. Eli Lilly and Company Recent Development
Table 124. F. Hoffmann-La Roche Ltd. Company Details
Table 125. F. Hoffmann-La Roche Ltd. Business Overview
Table 126. F. Hoffmann-La Roche Ltd. Product
Table 127. F. Hoffmann-La Roche Ltd. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020) (Million US$)
Table 128. F. Hoffmann-La Roche Ltd. Recent Development
Table 129. Five Prime Therapeutics, Inc. Company Details
Table 130. Five Prime Therapeutics, Inc. Business Overview
Table 131. Five Prime Therapeutics, Inc. Product
Table 132. Five Prime Therapeutics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020) (Million US$)
Table 133. Five Prime Therapeutics, Inc. Recent Development
Table 134. Genentech, Inc. Company Details
Table 135. Genentech, Inc. Business Overview
Table 136. Genentech, Inc. Product
Table 137. Genentech, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020) (Million US$)
Table 138. Genentech, Inc. Recent Development
Table 139. Incyte Corporation Company Details
Table 140. Incyte Corporation Business Overview
Table 141. Incyte Corporation Product
Table 142. Incyte Corporation Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020) (Million US$)
Table 143. Incyte Corporation Recent Development
Table 144. Johnson & Johnson Company Details
Table 145. Johnson & Johnson Business Overview
Table 146. Johnson & Johnson Product
Table 147. Johnson & Johnson Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020) (Million US$)
Table 148. Johnson & Johnson Recent Development
Table 149. MacroGenics, Inc. Company Details
Table 150. MacroGenics, Inc. Business Overview
Table 151. MacroGenics, Inc. Product
Table 152. MacroGenics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020) (Million US$)
Table 153. MacroGenics, Inc. Recent Development
Table 154. Novartis AG Company Details
Table 155. Novartis AG Business Overview
Table 156. Novartis AG Product
Table 157. Novartis AG Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020) (Million US$)
Table 158. Novartis AG Recent Development
Table 159. Oncogenex Pharmaceuticals, Inc. Company Details
Table 160. Oncogenex Pharmaceuticals, Inc. Business Overview
Table 161. Oncogenex Pharmaceuticals, Inc. Product
Table 162. Oncogenex Pharmaceuticals, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020) (Million US$)
Table 163. Oncogenex Pharmaceuticals, Inc. Recent Development
Table 164. PsiOxus Therapeutics Limited Company Details
Table 165. PsiOxus Therapeutics Limited Business Overview
Table 166. PsiOxus Therapeutics Limited Product
Table 167. PsiOxus Therapeutics Limited Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020) (Million US$)
Table 168. PsiOxus Therapeutics Limited Recent Development
Table 169. Research Programs/Design for This Report
Table 170. Key Data Information from Secondary Sources
Table 171. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Type: 2020 VS 2026
Figure 2. BMS-906024 Features
Figure 3. Buparlisib Hydrochloride Features
Figure 4. FP-1039 Features
Figure 5. Ipilimumab Features
Figure 6. JNJ-42756493 Features
Figure 7. Lenvatinib Features
Figure 8. Others Features
Figure 9. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Application: 2020 VS 2026
Figure 10. Research Center Case Studies
Figure 11. Hospital Case Studies
Figure 12. Clinic Case Studies
Figure 13. Squamous Non-Small Cell Lung Cancer Therapeutics Report Years Considered
Figure 14. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth 2015-2026 (US$ Million)
Figure 15. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Regions: 2020 VS 2026
Figure 16. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Regions (2021-2026)
Figure 17. Porter's Five Forces Analysis
Figure 18. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Players in 2019
Figure 19. Global Top Squamous Non-Small Cell Lung Cancer Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics as of 2019
Figure 20. The Top 10 and 5 Players Market Share by Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in 2019
Figure 21. North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. China Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Japan Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. India Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Central & South America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 28. Ascenta Therapeutics, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 29. Ascenta Therapeutics, Inc. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020)
Figure 30. AstraZeneca Plc Total Revenue (US$ Million): 2019 Compared with 2018
Figure 31. AstraZeneca Plc Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020)
Figure 32. AVEO Pharmaceuticals, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 33. AVEO Pharmaceuticals, Inc. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020)
Figure 34. Bayer AG Total Revenue (US$ Million): 2019 Compared with 2018
Figure 35. Bayer AG Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020)
Figure 36. BIND Therapeutics, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 37. BIND Therapeutics, Inc. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020)
Figure 38. Boehringer Ingelheim GmbH Total Revenue (US$ Million): 2019 Compared with 2018
Figure 39. Boehringer Ingelheim GmbH Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020)
Figure 40. Bristol-Myers Squibb Company Total Revenue (US$ Million): 2019 Compared with 2018
Figure 41. Bristol-Myers Squibb Company Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020)
Figure 42. Eli Lilly and Company Total Revenue (US$ Million): 2019 Compared with 2018
Figure 43. Eli Lilly and Company Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020)
Figure 44. F. Hoffmann-La Roche Ltd. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 45. F. Hoffmann-La Roche Ltd. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020)
Figure 46. Five Prime Therapeutics, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 47. Five Prime Therapeutics, Inc. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020)
Figure 48. Genentech, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 49. Genentech, Inc. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020)
Figure 50. Incyte Corporation Total Revenue (US$ Million): 2019 Compared with 2018
Figure 51. Incyte Corporation Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020)
Figure 52. Johns

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Nuclear Medicine Cyclotron Systems Market Report, History and Forecast 2018-2029

Published: 11-Jan-2024        Price: US 3350 Onwards        Pages: 118

The global Nuclear Medicine Cyclotron Systems market was valued at US$ 220.85 million in 2022 and will reach US$ 283.75 million by the end of 2029, growing at a CAGR of 4.38% during 2023-2029. Asia-Pacific market for Nuclear Medicine Cyclotron Systems was valued at $ 61.16 million in 2022 and will reach $ 104.22 million by 2029, at a CAGR of 5.84% during the forecast period of 2023 through 2029. Report Scope This report aims to provide a comprehensive presentation of the glo......

Global Non-imaging Diagnostic Catheter Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 95

The global Non-imaging Diagnostic Catheter market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......

Global Imaging Diagnostic Catheter Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 90

The global Imaging Diagnostic Catheter market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estimated......

Global PCR Equipment Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 77

The global PCR Equipment market was valued at US$ 806 million in 2023 and is anticipated to reach US$ 1230.7 million by 2030, witnessing a CAGR of 6.7% during The forecast period 2024-2030. PCR (Polymerase Chain Reaction) equipment is widely used in molecular biology and genetics research for amplifying DNA and RNA sequences. The market for PCR equipment is influenced by several key drivers. Here are some of The significant market drivers: Advancements in Research and Diagnost......

Global Disposable Sterile Syringes and Needles Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 109

The global Disposable Sterile Syringes and Needles market was valued at US$ 404.4 million in 2023 and is anticipated to reach US$ 539.1 million by 2030, witnessing a CAGR of 2.1% during The forecast period 2024-2030. North American market for Disposable Sterile Syringes and Needles is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Disposable Sterile Syringes and N......

Global Orthopaedic Power Tools Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106

The global Orthopaedic Power Tools market was valued at US$ 463.3 million in 2023 and is anticipated to reach US$ 746.5 million by 2030, witnessing a CAGR of 7.3% during The forecast period 2024-2030. North American market for Orthopaedic Power Tools is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Orthopaedic Power Tools is estimated to increase from $ million i......

Global Cerebrospinal Fluid Management Devices Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86

The global Cerebrospinal Fluid Management Devices market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Cerebrospinal Fluid Management Devices is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Cerebrospinal Fluid Management Devices is estimate......

Global CAD & CAM Milling Burs Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 79

The global CAD & CAM Milling Burs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for CAD & CAM Milling Burs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for CAD & CAM Milling Burs is estimated to increase from $ million in 2023 to reach $ ......

Global Artificial Teeth Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 98

The global Artificial Teeth market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Artificial Teeth is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Artificial Teeth is estimated to increase from $ million in 2023 to reach $ million by 2030, a......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs